Opioid Dependence, on Agonist Therapy

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Orexo
OrexoNJ - Morristown
2 programs
1
1
Higher bioavailability BNX sublingual tabletsPhase 41 trial
BNX sublingual tabletsPhase 31 trial
Active Trials
NCT01908842CompletedEst. Apr 2014
NCT01903005CompletedEst. Sep 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OrexoHigher bioavailability BNX sublingual tablets
OrexoBNX sublingual tablets

Clinical Trials (2)

NCT01903005OrexoHigher bioavailability BNX sublingual tablets

Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

Start: Jul 2013Est. completion: Sep 2014
Phase 4Completed
NCT01908842OrexoBNX sublingual tablets

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

Start: Aug 2013Est. completion: Apr 2014
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space